**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

A 43-year-old man developed manic episode with psychotic features during an off-label treatment with hydroxychloroquine, lopinavir/ritonavir and methylprednisolone \[*not all dosages and routes stated*\].

The man presented to an emergency department during COVID-19 outbreak in Spain. Regarding substances abuse, he revealed recognised ocassional cocaine use, but claimed about being abstinent for the last two weeks before hospitalisation. Police was called by his wife, because he was restless and more irritable after being hospitalised for COVID-19. He was verbally and physically aggressive. Prior to this episode, he presented with a bilateral pneumonia with mild respiratory insufficiency related to SARS-CoV-2 infection. He received off-label treatment with oral lopinavir/ritonavir and hydroxychloroquine during these 8 days. He achieved stable clinical response following the introduction of methylprednisolone at high doses. The only remarkable finding in blood analysis was found to be hyperglycaemia, which was related to corticosteroid treatment. During discharge, methylprednisolone 32 mg/day was prescribed for four more days. During the latest presentation, he was not taking any corticosteroid-therapy. A physical examination revealed no pathological findings. He did not have any fever or dyspnoea. A brain CT-scan was reported not observing intracranial acute pathology. Urine toxic screening was negative for cocaine, cannabis, opioids and benzodiazepines. A blood analysis demonstrated mild renal failure, which improved with IV hydration. Additionally, mild leukocytosis was noted, that was presumed to be related to agitation (which occurred due to hydroxychloroquine and lopinavir/ritonavir), since the following day it normalised. No other acute-phase reactants were altered.

Admission to a psychiatric inpatient unit was required for behavior management. An initial psychiatric evaluation was made, which showed the man to be hyper-alert and oriented. He was collaborative, but with a moderate level of psychomotor restlessness. His speech was loud, reiterative and logorrheic, with megalomaniac beliefs and persecutory delusions. He was expansive and anxious with a high level of self-perceived energy. Visual and auditory hallucinations were recognised along with eight-day global insomnia. During hospitalisation, a brain-MRI was performed, which showed no pathological results. Neurologic exam was normal. A new SARS-CoV-2 PCR test returned negative. The probability of encephalopathy of any type was therefore considered low. He had a full-recovery after 1-month of hospitalisation. During discharge, he was taking valproic acid, paliperidone, olanzapine and lorazepam. A diagnosis of substance/medication-induced manic episode with psychotic features was made \[*time to reaction onset not stated*\].
